3/27
06:17 am
rytm
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment [Yahoo! Finance]
3/26
09:01 am
rytm
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Low
Report
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
3/22
08:29 am
rytm
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity [Yahoo! Finance]
Medium
Report
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity [Yahoo! Finance]
3/22
03:17 am
rytm
Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch [Yahoo! Finance]
3/22
02:20 am
rytm
Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals EMANATE Phase 3 Misses Primary Endpoint, Sees Subgroup Signals for Setmelanotide [Yahoo! Finance]
3/20
08:03 pm
rytm
Rhythm obesity drug wins broader use from FDA [Yahoo! Finance]
Medium
Report
Rhythm obesity drug wins broader use from FDA [Yahoo! Finance]
3/20
12:58 pm
rytm
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
Low
Report
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
3/20
12:12 pm
rytm
Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide [Yahoo! Finance]
3/20
04:45 am
rytm
Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism [Yahoo! Finance]
3/19
06:30 pm
rytm
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
Medium
Report
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
3/18
08:03 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target lowered by HC Wainwright from $110.00 to $100.00. They now have a "buy" rating on the stock.
Medium
Report
Rhythm Pharmaceuticals (RYTM) had its price target lowered by HC Wainwright from $110.00 to $100.00. They now have a "buy" rating on the stock.
3/17
11:39 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Citigroup Inc. from $136.00 to $131.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Citigroup Inc. from $136.00 to $131.00. They now have a "buy" rating on the stock.
3/17
10:46 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Royal Bank Of Canada from $140.00 to $130.00. They now have an "outperform" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Royal Bank Of Canada from $140.00 to $130.00. They now have an "outperform" rating on the stock.
3/17
09:46 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Citizens Jmp from $176.00 to $152.00. They now have a "market outperform" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Citizens Jmp from $176.00 to $152.00. They now have a "market outperform" rating on the stock.
3/17
08:25 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Bank of America Corporation from $145.00 to $139.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Bank of America Corporation from $145.00 to $139.00. They now have a "buy" rating on the stock.
3/17
08:01 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Needham & Company LLC from $139.00 to $130.00. They now have a "buy" rating on the stock.
Medium
Report
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Needham & Company LLC from $139.00 to $130.00. They now have a "buy" rating on the stock.
3/17
08:01 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Morgan Stanley from $150.00 to $136.00. They now have an "overweight" rating on the stock.
Medium
Report
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Morgan Stanley from $150.00 to $136.00. They now have an "overweight" rating on the stock.
3/16
04:33 pm
rytm
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial [Yahoo! Finance]
3/16
04:01 pm
rytm
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
Low
Report
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
3/16
01:18 pm
rytm
Rhythm Pharmaceuticals: Rare Genetic Obesity Player With Upcoming PDUFA [Seeking Alpha]
Low
Report
Rhythm Pharmaceuticals: Rare Genetic Obesity Player With Upcoming PDUFA [Seeking Alpha]
3/16
07:38 am
rytm
Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision [Seeking Alpha]
Low
Report
Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision [Seeking Alpha]
3/12
09:10 am
rytm
Rhythm Pharmaceuticals (RYTM) was given a new $143.00 price target by Telsey Advisory Group.
Low
Report
Rhythm Pharmaceuticals (RYTM) was given a new $143.00 price target by Telsey Advisory Group.
3/12
08:07 am
rytm
Rhythm Pharmaceuticals (RYTM) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Low
Report
Rhythm Pharmaceuticals (RYTM) had its "overweight" rating reaffirmed by Wells Fargo & Company.
3/3
06:06 pm
rytm
Rhythm Pharmaceuticals (RYTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Rhythm Pharmaceuticals (RYTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/3
08:54 am
rytm
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright [Yahoo! Finance]